MOLICA, MATTEO

MOLICA, MATTEO  

Mostra prodotti
Risultati 1 - 20 di 32 (tempo di esecuzione: 0.065 secondi).
Titolo Data di pubblicazione Autore(i) File
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors. 2017 Molica, M; Canichella, M; Colafigli, G; Latagliata, R; Diverio, D; Alimena, G; Foà, R; Breccia, M.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2018 Caocci, Giovanni; Mulas, Olga; Annunziata, Mario; Luciano, Luigiana; Bonifacio, Massimiliano; Orlandi, Ester Maria; Pregno, Patrizia; Galimberti, Sara; Russo Rossi, Antonella; Abruzzese, Elisabetta; Iurlo, Alessandra; Martino, Bruno; Sgherza, Nicola; Binotto, Gianni; Castagnetti, Fausto; Gozzini, Antonella; Fozza, Claudio; Bocchia, Monica; Sicuranza, Anna; Stagno, Fabio; Efficace, Fabio; Usala, Emilio; De Gregorio, Fiorenza; Scaffidi, Luigi; Elena, Chiara; Pirillo, Francesca; Baratè, Claudia; Trawinska, Malgorzata Monika; Cattaneo, Daniele; Labate, Claudia; Gugliotta, Gabriele; Molica, Matteo; Specchia, Giorgina; La Nasa, Giorgio; Foà, Robin; Breccia, Massimo
Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). 2015 Morano, Sg; Latagliata, R; Girmenia, C; Massaro, F; Berneschi, P; Guerriero, A; Giampaoletti, M; Sammarco, A; Annechini, G; Fama, A; DI ROCCO, Alice; Chistolini, Antonio; Micozzi, Alessandra; Molica, Matteo; Barberi, Walter; Minotti, C; Brunetti, Ga; Breccia, M; Cartoni, C; Capria, S; Rosa, G; Alimena, Giuliana; Foa, Roberto
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events 2018 Molica, Matteo; Scalzulli, Emilia; Colafigli, Gioia; Alunni Fegatelli, Danilo; Massaro, Fulvio; Latagliata, Roberto; Foà, Robin; Breccia, Massimo
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort 2021 Chiatamone Ranieri, S.; Arleo, M. A.; Trasarti, S.; Bizzoni, L.; Carmosino, I.; De Luca, M. L.; Mohamed, S.; Mariggio, E.; Scalzulli, E.; Rosati, S.; De Benedittis, D.; Colafigli, G.; Pepe, S.; Molica, M.; Scamuffa, M. C.; Di Prima, A.; Ferretti, A.; Baldacci, E.; Mancini, M.; Santoro, C.; Vignetti, M.; Breccia, M.; Latagliata, R.
Clinical characteristics and outcome of patients with autoimmune hemolytic anemia (AIHA) uniformly defined as primary by a diagnostic work-up 2016 Mauro, Francesca Romana; Coluzzi, S; Paoloni, F; Trastulli, F; Armiento, Daniele; Ferretti, Antonietta; Giovannetti, Gianluca; Colafigli, Gioia; Molica, Matteo; LA ROCCA, Ursula; De Propris, Ms; Caronna, Roberto; Morano, G; Guarini, Anna; Girelli, Gabriella; Foa, Roberto
Clinical Results According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: the Younger, the Later, the Worse? In corso di stampa Latagliata, Roberto; Breccia, Massimo; Carmosino, Ida; Cesini, Laura; De Benedittis, Daniela; Mohamed, Sara; Vozella, Federico; Molica, Matteo; Campanelli, Melissa; De Luca, Maria Lucia; Colafigli, Gioia; Quattrocchi, Luisa; Loglisci, Maria Giovanna; Massaro, Fulvio; Canichella, Martina; Diverio, Daniela; Mancini, Marco; Alimena, Giuliana; Foà, Robin
Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront 2015 Breccia, M; Molica, Matteo; Colafigli, Gioia; Zacheo, I; Latagliata, Angelo Raffaele; Tafuri, Agostino; Alimena, Giuliana
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response 2016 Latagliata, R.; Romano, A.; Mancini, M.; Breccia, M.; Carmosino, I.; Vozella, F.; Montagna, C.; Volpicelli, P.; De Angelis, F.; Petrucci, L.; Serrao, A.; Molica, M.; Salaroli, A.; Diverio, D.; Alimena, G.
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials 2017 Molica, Matteo; Canichella, Martina; Alunni Fegatelli, Danilo; Colafigli, Gioia; Massaro, Fulvio; Latagliata, Roberto; Foà, Robin; Breccia, Massimo
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice 2019 Scalzulli, Emilia; Molica, Matteo; Alunni Fegatelli, Danilo; Colafigli, Gioia; Rizzo, Lorenzo; Mancini, Marco; Efficace, Fabio; Latagliata, Roberto; Foà, Robin; Breccia, Massimo
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 2019 Breccia, M.; Bartoletti, D.; Bonifacio, M.; Palumbo, G. A.; Polverelli, N.; Abruzzese, E.; Bergamaschi, M.; Tieghi, A.; Tiribelli, M.; Iurlo, A.; Cavazzini, F.; Sgherza, N.; Binotto, G.; Isidori, A.; D'Adda, M.; Crugnola, M.; Bosi, C.; Heidel, F.; Molica, M.; Scaffidi, L.; Cattaneo, D.; Latagliata, R.; Auteri, G.; Lemoli, R. M.; Fanin, R.; Russo, D.; Aversa, F.; Cuneo, A.; Semenzato, G.; Catani, L.; Cavo, M.; Vianelli, N.; Foa, R.; Palandri, F.
Improvement of bone marrow fibrosis with ruxolitinib: Will this finding change our perception of the drug? 2015 Breccia, Massimo; Molica, Matteo; Colafigli, Gioia; Alimena, Giuliana
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 2019 Caocci, G.; Mulas, O.; Abruzzese, E.; Iurlo, A.; Annunziata, M.; Orlandi, E. M.; Galimberti, S.; Binotto, G.; Sgherza, N.; Luciano, L.; Martino, B.; Russo Rossi, A.; DI BONIFACIO, Marco; Fozza, C.; Trawinska, M. M.; Cattaneo, D.; Elena, C.; Barate, C.; De Gregorio, F.; Molica, M.; La Nasa, G.; Foa, R.; Breccia, M.
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib 2019 Cesini, L.; Carmosino, I.; Breccia, M.; De Benedittis, D.; Mohamed, S.; De Luca, M. L.; Colafigli, G.; Molica, M.; Scalzulli, E.; Massaro, F.; Mariggio, E.; Rizzo, L.; Loglisci, M. G.; Scamuffa, M. C.; Vozella, F.; Diverio, D.; Mancini, M.; Alimena, G.; Foa, R.; Latagliata, R.
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia 2019 Molica, Matteo; Scalzulli, Emilia; Colafigli, Gioia; Foà, Robin; Breccia, Massimo
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy 2015 Breccia, Massimo; Stefania de Propris, Maria; Molica, Matteo; Colafigli, Gioia; Minotti, Clara; Diverio, Daniela; Latagliata, Roberto; Guarini, Anna; Lo Coco, Francesco; Foa, Roberto
Life-Threatening Autoimmune Hemolytic Anemia and Idhiopatic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization 2016 Molica, Matteo; Massaro, Fulvio; Annechini, Giorgia; Baldacci, Erminia; D'Elia, Gianna Maria; Rosati, Riccardo; Trisolini, Silvia Maria; Volpicelli, Paola; Foa, Roberto; Capria, Saveria
LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE MOLECULAR RESPONSE WITH ALPHA-INTERFERON AFTER TREATMENT DISCONTINUATION 2014 Latagliata, R; Romano, A; Mancini, M; Breccia, M; Carmosino, I; Vozella, F; Montagna, C; Volpicelli, P; Petrucci, L; Serao, A; Molica, M; Salaroli, A; Diverio, D; Tafuri, Agostino; Alimena, Giuliana
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. 2017 Molica, M; Breccia, M; Colafigli, G; Massaro, F; Quattrocchi, L; Mancini, M; Diverio, D; Latagliata, R; Foà, R.